InterCure Ltd. INCR PHARMA
Company Overview
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Recent Developments
- Dec 2025 Revenue of $270.20M (+13.1% YoY); net profit $-35.71M.
- Trailing 12 Months Year-on-year growth — revenue +23.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -11.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -11.41% |
| 1 Year: | 23.90% |
Stock Price Performance
| 1 Year: | +228.66% |
| 6 Months: | +31.46% |
| 3 Months: | +8.89% |
| 1 Month: | +10.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)54.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -11.4% CAGR over 5 years.
- Trading 35.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INCR InterCure Ltd. PHARMA | 5.39 | -4.94 | $80.87M | 0.00% | 1.41% | -9.27% | -11.41% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 388.68M | 355.55M | 238.84M | 270.20M |
| Cost of Revenue | - | 233.60M | 250.46M | 208.61M | 237.02M |
| Gross Profit | - | 155.08M | 105.09M | 30.23M | 33.18M |
| Operating Expenses | - | 113.88M | 67.50M | 75.29M | 26.45M |
| Operating Income | - | 41.20M | 37.59M | -45.06M | 6.73M |
| EBITDA | - | 70.23M | -23.90M | -51.31M | -7.29M |
| Interest Expense | - | 14.69M | 24.22M | 20.64M | 19.66M |
| Pretax Income | - | 43.84M | -61.28M | -87.32M | -44.10M |
| Tax Provision | - | 93.00K | 2.25M | -14.53M | -7.32M |
| Net Income | - | 44.82M | -61.96M | -67.80M | -35.71M |
| Diluted EPS | 0.10 | 0.99 | -1.36 | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 958.01M | 786.61M | 762.57M | 690.55M |
| Current Assets | - | 527.49M | 418.80M | 391.80M | 316.75M |
| Cash & Equivalents | - | 232.59M | 101.14M | 78.32M | 46.47M |
| Inventory | - | 146.50M | 106.29M | 125.33M | 108.06M |
| Receivables | - | 36.92M | 60.41M | 51.85M | 21.18M |
| Total Liabilities | - | 436.53M | 329.55M | 364.90M | 294.19M |
| Current Liabilities | - | 312.72M | 225.87M | 226.75M | 214.37M |
| Long Term Debt | - | 99.68M | 82.20M | 113.98M | 59.46M |
| Total Debt | - | 255.16M | 195.68M | 211.40M | 183.01M |
| Total Equity | - | 501.31M | 455.11M | 396.97M | 396.52M |
| Shares Outstanding | - | 45.57M | 45.57M | 47.16M | 54.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 51.27M | -53.63M | -66.93M | 16.84M |
| Investing Cash Flow | - | -142.50M | 4.77M | 17.69M | -1.99M |
| Financing Cash Flow | - | 120.45M | -82.89M | 26.45M | -46.66M |
| Capital Expenditure | - | -19.74M | -2.62M | -4.38M | -3.55M |
| Free Cash Flow | - | 31.52M | -56.25M | -71.30M | 13.29M |
| Net Change in Cash | - | 29.22M | -131.75M | -22.78M | -31.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 39.9% | 29.6% | 12.7% | 12.3% |
| Operating Margin % | - | 10.6% | 10.6% | -18.9% | 2.5% |
| Net Margin % | - | 11.5% | -17.4% | -28.4% | -13.2% |
| ROE % | - | 8.9% | -13.6% | -17.1% | -9.0% |
| ROCE % | - | 6.4% | 6.7% | -8.4% | 1.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INCR
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement - markets.businessinsider.com
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOcWFDbFgzV0tJdzBtREVYX2diMnNucmhVN3Vhb0EwV0NWMll6Zi1EZ01Yb1VSaWhvS2xXem1xZFdGNnFFdTlWMldTSkp4SUd6UU1CbUJqMTRSckpwQ3NMV1UwN3g0d3VPbFJYODhBYlZXd1IzXzVfNGpmV1dJZTZvLUR4SUt5VVlxUW5SUj…
(INCR) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNT2FjY1NjSWdhRUt1VENwbWl5MENfVkcwVjdpU1A2bTJwM0gzaHJhOEQ3eEJHYk5vUi16eHB1ZHlSckVJS0pYdElPbFR3UFRnTVdrSnFsVTItdmFlcFRSTEdxT1FQUmpvZjkydkVSOWp3bWthaTJwb3dqSGlDQWVsOFlXYTEyRnBFMmZ5aj…
InterCure Secures NIS 22 Million Private Placement With Potential to Rise to NIS 54 Million for Global Expansion - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOZzVyYmZxcndiVzRaM1NrWmxrbTBSSWxuMG8yZFc4WVpJMGxoVzhIOGt4TEdrYTNNeWZJRGlZVjF0VV90OXByWkl1T04zd0xnaUhxTDNicWUtdXlQNzY5bF9lTVB3MDYteVVaVVdRUDBmODVfUm1hU3pMa2NIN1pfay1laHZaQTlDamZCSW…
InterCure reaches an approximately $77 million settlement after attacks damaged its cannabis facility - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPS1BMTldrQUw0MFVYOXJvY2YzZUFOU0tFTWp4c3VmWmxWVGxqaS1oZ3FnZ2hQUUI5REt3MHdET01uNU54UGlhYmpDVlBvSV9CQnZFRXh1Rzg2cFlQeHN0NWh5N2o0RTAydkR1MGlWZUpzRXp3dEw2V2dFMlRXajZsREEyR2xPUERwQm1XV3…
INCR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE8tLWNVN29Ka2l2cDRtOTFtdmdkbEFiNkdja0pWMm03amhRQTFnaEVnemVSNW9Yay1tZW5pUUJMQk5COUl3TGc?oc=5" target="_blank">INCR</a> <font color="#6f6f6f">Finviz</font>…
InterCure Ltd. (NASDAQ: INCR) Share Price, INCR Stock News, INCR Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5RbFRFZmNfZTlMZmIyNUtOd1RvZ0JmTGNId1cySlRMdmwwc3laa0xORnY2RHc5aFpvbWltMTRDQkVHamNjZi1SSEVTODV6bllzOVMteThR?oc=5" target="_blank">InterCure Ltd. (NASDAQ: INCR) Share Price, INCR Sto…
INCR — Frequently Asked Questions
What is the current share price of InterCure Ltd. (INCR)?
As of 2026-09-19 21:16 PDT, InterCure Ltd. (INCR) trades at $5.39 on NasdaqGM. Its 52-week range is $1.58 to $8.40.
What is the market capitalisation of INCR?
InterCure Ltd. (INCR) has a market capitalisation of $80.87M on NasdaqGM.
What is the P/E ratio of INCR?
INCR trades at a trailing price-to-earnings (P/E) ratio of -4.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.70.
What is the return on equity (ROE) of INCR?
INCR has a return on equity (ROE) of -9.27%. Its return on capital employed (ROCE) is 1.41%.
Is INCR a good stock to buy?
This page provides a data-driven analysis of InterCure Ltd. (INCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.